Related references
Note: Only part of the references are listed.SNP-based mapping arrays reveal high genomic complexity in monoclonal gammopathies, from MGUS to myeloma status
L. Lopez-Corral et al.
LEUKEMIA (2012)
HAEMATOLOGICAL CANCER Redefining myeloma
S. Vincent Rajkumar et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
Incidence of Monoclonal Gammopathy of Undetermined Significance and Estimation of Duration Before First Clinical Recognition
Terry M. Therneau et al.
MAYO CLINIC PROCEEDINGS (2012)
Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs myeloma
B. Paiva et al.
LEUKEMIA (2011)
Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma
W-J Chng et al.
LEUKEMIA (2011)
Diagnosis of Smoldering Multiple Myeloma
S. Vincent Rajkumar et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Impact of optimal follow-up of monoclonal gammopathy of undetermined significance on early diagnosis and prevention of myeloma-related complications
Giada Bianchi et al.
BLOOD (2010)
Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells
Ernesto Perez-Persona et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management
R. A. Kyle et al.
LEUKEMIA (2010)
A monoclonal gammopathy precedes multiple myeloma in most patients
Brendan M. Weiss et al.
BLOOD (2009)
Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study
Ola Landgren et al.
BLOOD (2009)
Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma
R. A. Kyle et al.
LEUKEMIA (2009)
Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma
Angela Dispenzieri et al.
BLOOD (2008)
Improved survival in multiple myeloma and the impact of novel therapies
Shaji K. Kumar et al.
BLOOD (2008)
Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma
Robert A. Kyle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Monoclonal gammopathy of undetermined significance:: Predictors of malignant transformation and recognition of an evolving type characterized by a progressive increase in M protein size
Laura Rosinol et al.
MAYO CLINIC PROCEEDINGS (2007)
Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance
S Kumar et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance
SV Rajkumar et al.
BLOOD (2005)
Smoldering multiple myeloma: natural history and recognition of an evolving type
L Rosinol et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
A long-term study of prognosis in monoclonal gammopathy of undetermined significance
RA Kyle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Share Paper
